
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is well positioned for continued success with its dominant market position and innovative technology, as confirmed by ophthalmologists. The recent upgrade and raised price target reflect this potential, driven by strong Q1 results, optimism for a rebound in China, and successful new product launches. Additionally, the company's premium pricing for EVO+ should contribute to profitability.
Bears say
Staar Surgical is heavily reliant on its ICL products, which face stiff competition from corneal-based alternatives and laser procedures. While the company's ICL have a unique selling point of reversibility, its high cost and steep learning curve for doctors may hinder its adoption. Furthermore, the company's heavy reliance on foreign sales, particularly from China, presents a risk given geopolitical and macroeconomic uncertainties and the company's lack of formal revenue and earnings guidance.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares